If you want to know what the evidence for TB-500 actually looks like — not what a supplier's product page says it looks like — someone has now done the tedious work. A scoping review published in Applied Sciences in 2026 screened 1,772 records on thymosin beta-4 and TB-500 for anything relevant to tissue healing and musculoskeletal repair, and included 80 of them. Of those 80 studies, the number that tested TB-500 itself was one.

That single number is the most useful thing in the TB-500 research literature right now, and it explains why this compound occupies such an odd space in Australia: heavily controlled, heavily discussed online, and almost entirely unstudied in the form people actually talk about.

What Is TB-500, And Why The Distinction Matters

Thymosin beta-4 (Tβ4) is a 43–44 amino acid actin-sequestering protein found in most human cells and in wound fluid. TB-500 is a shorter synthetic fragment marketed as a stand-in for it. The two are related but not interchangeable — they differ in length, and by extension in stability, pharmacokinetics and the range of effects they've been shown to produce.

That distinction is not pedantry. It's the reason the review's headline finding lands so hard: nearly the entire "TB-500 evidence base" that circulates in forums and marketing copy is actually thymosin beta-4 evidence, borrowed. You can read more background on the compound in our TB-500 profile.

The 2026 Evidence Map: 1,772 Records, 80 Studies

The review, from a group in the Department of Physical Medicine & Rehabilitation at the University of Utah (McGuire, Hughes, Maak and Cushman), set out to map — not grade — the literature. Scoping reviews do that deliberately: they describe where evidence sits rather than pooling it into a treatment effect.

The breakdown of the 80 included studies:

  • 27 (33.8%) mixed studies
  • 23 (28.8%) in vitro
  • 19 (23.8%) human
  • 11 (13.8%) animal

So roughly three in four included studies were cell work, animal work, or a mix. That alone is not damning — early-stage science has to start somewhere. The problem is where the human work clustered.

The human studies aren't about tendons

Human evidence, the authors report, was concentrated in ocular/cornea and wound/skin/soft tissue settings. The tissue categories that TB-500 is popularly associated with — tendon, ligament, muscle, cartilage, spine and intervertebral disc — were "comparatively sparse."

In other words: the indications with actual human data are dry eye, corneal injury and chronic skin ulcers. The indications people buy it for are the ones with the least direct evidence. The review's own conclusion is that the literature "remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications."

One study, out of eighty

And then the finding that should end most online arguments: direct TB-500 evidence was limited to a single included study. One, out of 80, after screening 1,772 records.

This is consistent with the regulatory position we've covered before — there are no human trials supporting TB-500's injury-recovery use. What's new here is that someone has quantified the gap systematically rather than asserting it.

Where The Real Thymosin Beta-4 Money Is Going

Worth noting, because it shows the molecule isn't a dead end scientifically: the live commercial development programme for thymosin beta-4 is cardiac, not musculoskeletal.

Beijing Northland Biotech is developing a recombinant human thymosin beta-4 injection (NL005) for acute myocardial infarction. A Phase IIb study completed in 2023, and a multicentre, randomised, double-blind, placebo-controlled Phase IIc trial (NCT07586865) has an estimated start of May 2026 with primary completion estimated for August 2027. Registration is not evidence — Phase IIc means efficacy is still an open question, and no results are available.

Two things follow. First, if thymosin beta-4 works somewhere in humans, the heart-attack setting is where we'll find out first. Second, nobody with capital is running a Phase III for tendon repair, which tells you something about how the people closest to the molecule read the preclinical data.

Is TB-500 Legal In Australia?

Short answer: not for general human use, and possession is controlled.

Following an ACMS/ACCS scheduling consideration in February 2016, thymosin beta-4 and TB-500 were given Schedule 4 and Appendix D, Item 5 entries in the Poisons Standard, with the Appendix D possession controls in force from June 2016. Appendix D lists substances where additional controls apply to possession or supply beyond ordinary prescription-only status. The stated purpose of the scheduling was to control how these substances were advertised, sold and accessed without legitimate purpose.

Practically, that means:

  • No TGA-registered product. There is no approved thymosin beta-4 or TB-500 medicine in Australia for any indication.
  • Possession is restricted, not merely prescription-gated — Appendix D goes further than Schedule 4 alone.
  • Prohibited in sport at all times under WADA's peptide hormones/growth factors category. Sport Integrity Australia lists thymosin beta-4 explicitly.

The enforcement precedent is unusually concrete for a peptide. In January 2016, the Court of Arbitration for Sport found anti-doping violations against 34 Essendon players in relation to thymosin beta-4. That case, more than any journal article, is why this compound is a named, scheduled entity in Australian law rather than a grey-market curiosity.

How To Read TB-500 Claims From Here

A workable filter, drawn straight from the review's structure:

  1. Ask which molecule was tested. If the citation is thymosin beta-4, it is not a TB-500 result.
  2. Ask which tissue. Cornea and skin ≠ tendon and muscle.
  3. Ask which species. Three-quarters of the mapped literature isn't human.
  4. Ask whether it's replicated. The pyroptosis, neuro and hair-growth signals doing the rounds are early, single-lab and unreplicated.

Apply those four and most of the confident claims about TB-500 collapse into "plausible mechanism, no human outcome data." That's not the same as "doesn't work" — it's an honest description of a field that hasn't been tested yet.

For how this compares with other repair-adjacent compounds, see our wider peptides library. And if you want new primary research on this space summarised as it lands, join the free updates list.

FAQ

What is TB-500 used for in research?

In the mapped literature, thymosin beta-4 has mostly been studied in wound/skin, vascular/endothelial, ocular/cornea and bone models. The popular uses — tendon, ligament and muscle repair — are exactly the areas the 2026 scoping review found to be sparse, and human data there is essentially absent.

Is TB-500 legal in Australia?

TB-500 and thymosin beta-4 hold Schedule 4 and Appendix D, Item 5 entries in the Poisons Standard, with Appendix D possession controls in force since June 2016. There is no TGA-approved product, and both are prohibited in sport at all times under WADA rules.

Are there human trials of TB-500?

Not for injury recovery. A 2026 scoping review of 80 studies found direct TB-500 evidence in just one included study; almost all human data involves thymosin beta-4 itself, mainly in eye and skin conditions.

Does TB-500 heal tendons or muscle?

There is no human trial evidence that it does. Preclinical work suggests plausible mechanisms involving actin binding, cell migration and angiogenesis, but the 2026 review specifically flagged tendon, ligament, muscle and cartilage as under-represented tissue categories.

Sources

This article is information, not medical advice. TB-500 and thymosin beta-4 are not approved by the TGA for any human use, carry Schedule 4 and Appendix D controls in Australia, and are prohibited in sport. retatrutide.net.au is independent, does not sell or source any compound, and does not tell readers where to obtain one.